SG-SBPH@EC2603B

China BioPharmaceutical Obtains NMPA Approval for Benmelstobart Injection Marketing

China Biologic Products' Benmelstobart Injection Receives New Indication Approval

China Bio-Pharmaceutical Completes Phase III Clinical Enrollment for Two Drugs

China Bio-Pharmaceutical Completes Phase III Clinical Trial Enrollment For TQB2102 In HER2 Low-Expression Breast Cancer

China Biopharmaceutical Completes Patient Recruitment for LM-302's Phase III Clinical Trial

Bocom International Maintains Buy Rating on China Bio

CMBI Adjusts China Bio-Pharmaceutical's Net Profit Forecast and Maintains Buy Rating

China BioPharm Ltd. Announces Positive Phase II Clinical Trial Results for TQA3605 in Chronic Hepatitis B Treatment

China Biopharmaceutical Acquires Herjia for 120 Million

China Biopharmaceutical Announces Acquisition of Hygieia Biotech

China Biology Pharmaceutical Announces Willingness to Acquire More Biotech Companies in China and Seek Cross-border Cooperation

China Bio-Pharmaceutical acquires 100% equity of Herjia

CSOBP Management Outlines Business Prospects and Expresses Optimism on National Medical Insurance Negotiations

China Biopharmaceuticals receives executive 增持

China Biopharma Initiates Phase III Clinical Trial of TDI01 for Idiopathic Pulmonary Fibrosis

China Biologic Completes Phase II Clinical Trials for Psoriasis Drug TQH3906

Xie Xin Increased Holdings in China Bio-Pharmaceuticals

Nomura Downgrades China Biologic Products Target Price to HKD 8.3

Chinese Innovative Pharmaceutical Companies Discuss Overseas Strategies: From 'Riding Others' Ships' to 'Building Their Own Ships'

Zentelxin (Cumbexil) Approved for Market by Chong Kun Dang Pharmaceutical

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

516820

159102

589720

516500

01177

159929

159837

512290

588250

560600

159859

588130

159849

588860

Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing

marketscreener

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

SINO BIOPHARM

China Universal 800 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing

520880

159506

520690

Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maintenance therapy in patients with unresectable stage III non-small cell lung cancer. This approval is based on positive phase III trial results and positions Sino Biopharmaceutical as a strong competitor in China's lung cancer market. The stock currently holds a Hold rating with a price target of HK$7.90. The company focuses on innovative drug development, particularly in oncology, and has a market cap of HK$116.6B.

Tip Ranks

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug

01093

01801

02269

08189

08037

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Wallstreetcn

CSPC PHARMA

INNOVENT BIO

WUXI BIO

TEDA BIOMEDICAL

CH BIOTECH SER

QYUNS-B

516930

512010

510660

159992

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

513060

513700

513120

Sino Biopharmaceutical Limited has completed enrollment for a Phase III clinical trial of TQB2102, a HER2 bispecific antibody-drug conjugate, targeting HER2-low recurrent or metastatic breast cancer. The trial, named TQB2102-III-01, will compare the efficacy and safety of TQB2102 against standard chemotherapy. Results are pending. This announcement was published via the Hong Kong Stock Exchange.

Reuters

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer

Sino Biopharm's LM-302 Completes Phase 3 Trial Enrollment in Gastric Cancer Study

Sino Biopharm's LM-302 Completes Phase 3 Trial Enrollment in Gastric Cancer Study

Sino Biopharmaceutical’s subsidiary, LaNova Medicines, has completed Phase III enrollment for tecotabart vedotin (LM-302), the first CLDN18.2 ADC to reach this milestone. This trial targets advanced gastric and gastroesophageal junction adenocarcinoma. Early data shows promising response rates, and a Phase III first-line trial is planned in China. The company aims to enhance its oncology portfolio and global competitiveness, with regulatory support in China and the U.S. The current analyst rating for Sino Biopharmaceutical (HK:1177) is a Hold with a price target of HK$7.50.

Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment

Sino Biopharmaceutical Limited has announced the successful completion of patient enrollment for the Phase III registration study of Tecotabart Vedotin (LM-302), an antibody-drug conjugate targeting CLDN18.2. The study focuses on patients with CLDN18.2-positive, locally advanced or metastatic gastric and gastroesophageal junction carcinoma in third-line and later therapy. LM-302 is the first CLDN18.2-ADC to complete patient enrollment in a pivotal Phase III study. Early phase study results combining LM-302 with Toripalimab were presented at the ASCO Annual Meeting 2025.

JUNSHI BIO

Junshi Biosciences

Sino Biopharmaceutical meldet Abschluss der Patienteneinschreibung für Phase-III-Studie von Tecotabart Vedotin bei Magenkrebs

SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low-price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking, indicating a strong wait-and-see sentiment among incremental funds in the market. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, and there is considerable divergence between bulls and bears in the short term. 

Fundamentally, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it is affected by industry medical insurance cost control, centralized procurement pressures, and a slowdown in quarter-on-quarter performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading activity. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic headwinds that have further suppressed risk appetite for funds. 

Technically, current support is located in the HKD 3.5-3.8 range, which has historically seen rebounds after multiple touches. However, the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. Conversely, if the price breaks support on reduced volume, there may be a risk of inertia-driven declines. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes alongside unusual movements in incremental funds, light positions may be considered for short-term opportunities, with an overall focus on stability and risk control as a priority

Technical Forecast

Yinhua CSI Research Sector 100 ETF

Morning Trend | SINO BIOPHARM retraces to a low, will the rebound window open?

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

Hengrui Pharma

3SBIO

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

SG-SBPH@EC2603B(20799.HK)

Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing

Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer